From CBC News.

Health Canada says it’s reviewing nine submissions for generic versions of popular weight loss medications that pharmaceutical experts say could bring down the price.

The submissions in Canada are for generic forms of semaglutide, the active ingredient in Novo Nordisk’s injectable prescription drugs Ozempic and Wegovy, which have been approved by Health Canada for diabetes and weight loss respectively.

CBC News also asked Health Canada if it has received an application for a pill form of Wegovy from Novo Nordisk, or a generic version of the medication in pill form.

"While Health Canada cannot confirm when submissions are filed by a manufacturer, the department does post regular updates about submissions that have been accepted for review on the Submissions Under Review list," the regulator responded on Wednesday.

»»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS

For breaking news, video, audio and in-depth coverage: https://www.cbc.ca/news
Follow CBC News on TikTok: https://www.tiktok.com/@cbcnews
Subscribe to CBC News on Snapchat: https://bit.ly/3leaWsr
Subscribe to CBC News on WhatsApp: https://www.whatsapp.com/channel/0029Vb6MSjH9Bb63S9tbQa1Y

Download the CBC News app for iOS: http://apple.co/25mpsUz
Download the CBC News app for Android: http://bit.ly/1XxuozZ

»»»»»»»»»»»»»»»»»»
For more than 80 years, CBC News has been the source Canadians turn to, to keep them informed about their communities, their country and their world. Through regional and national programming on multiple platforms, including CBC Television, CBC News Network, CBC Radio, CBCNews.ca, mobile and on-demand, CBC News and its internationally recognized team of award-winning journalists deliver the breaking stories, the issues, the analyses and the personalities that matter to Canadians.